Posts by DAY Vision

[vc_row][vc_column][vc_column_text]FRAMINGHAM, MA, May 16, 2011 – Dilon Devices, Inc. today announced that the U.S. Food and Drug Administration (FDA) formally accepted for filing the company’s Pre-Market Approval (PMA) application for the MarginProbe™ System. The FDA’s actions mean that the PMA application was sufficiently complete and ready for substantive review. Additionally, the FDA believes MarginProbe represents…

[vc_row][vc_column][vc_column_text]Framingham, MA, July 09, 2010 – Dilon Devices, Inc. today announced that positive interim results from a European post-market study of the MarginProbe™ System, a technology to enable better detection and removal of cancerous tissue during breastconserving surgery (BCS), were presented at the German Breast Cancer Society Meeting (DGS 2010) held in Hamburg, Germany from…

[vc_row][vc_column][vc_column_text]New York, January 12, 2010 — Dilon Devices today announced the completion of patient enrollment in the MarginProbe™ pivotal clinical trial. The MarginProbe procedure provides surgeons with real-time detection of cancer at the edges of the tissue removed during breast conservation surgery (BCS), which is the only way to ensure the complete removal of the…

[vc_row][vc_column][vc_column_text]Caesarea, Israel and New York, NY, March 12, 2009 – Dilon Devices, a developer of cancer detection devices, today announced the appointment of William Densel as President U.S. and Chief Business Officer. Dilon Devices is engaged in the development and commercialization of intraoperative devices for the real-time detection of cancerous tissues. The company’s initial product,…